April 2014, Part 1
Introducing Immunotherapy in Oncology: A 4-Part Supplement Series to Personalized Medicine in Oncology
Personalized Medicine in Oncology (PMO) is proud to present a 4-part supplement series to our reading community focused on the timely issue of immunotherapy and its role in personalizing cancer care. Harnessing the power of the immune system to combat cancer is not a new idea; however, the new generation of immunotherapeutic agents has captured the imagination of those in the oncology community and sparked a renewed interest in the potential capabilities of an empowered immune system.
Immunotherapy in Oncology will explore the new generation of immunotherapies as monotherapy, as well as in combination with molecularly targeted therapies: the combination of these agents has been shown to complement each other’s mechanisms and may possess therapeutic synergy. Immunotherapy has a significant role in today’s treatment of patients with cancer, and it is imperative that physicians and patients have knowledge of the latest information in immunotherapy’s offerings.
We hope this offering empowers you to provide the very best in patient care.
Sanjiv S. Agarwala, MD
St. Luke’s Medical Center PMO Editor in Chief
With several agents now approved and broadly available for the treatment of patients with advanced renal cell carcinoma (RCC), a great deal of attention has been focused on determining the most appropriate sequence of therapies. The concept of sequential therapy has developed for several reasons, including: (1) the availability of [ Read More ]
For decades, chemotherapy, radiation therapy, and excisional surgery have served as the mainstays of cancer treatment. While often effective, these treatments affect healthy as well as neoplastic cells and therefore cause many unintended side effects, some of which may be life-threatening. Even after treatment, a substantial proportion of patients experience [ Read More ]